Exploiting antitumor immunity to overcome relapse and improve remission duration

Cancer survivors often relapse due to evolving drug-resistant clones and repopulating tumor stem cells. Our preclinical study demonstrated that terminal cancer patient’s lymphocytes can be converted from tolerant bystanders in vivo into effective cytotoxic T-lymphocytes in vitro killing patient’s ow...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lei L., Chen, Xinjian, Choi, Haesun, Sang, Hongxun, Chen, Leo C., Zhang, Hongbo, Gouw, Launce, Andtbacka, Robert H., Chan, Benjamin K., Rodesch, Christopher K., Jimenez, Arnie, Cano, Pedro, Jones, Kimberly A., Oyedeji, Caroline O., Martins, Tom, Hill, Harry R., Schumacher, Jonathan, Willmore, Carlynn, Scaife, Courtney L., Ward, John H., Morton, Kathryn, Lor Randall, R., Lazar, Alexander J., Patel, Shreyaskumar, Trent, Jonathan C., Frazier, Marsha L., Lin, Patrick, Jensen, Peter, Benjamin, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378844/
https://www.ncbi.nlm.nih.gov/pubmed/22198309
http://dx.doi.org/10.1007/s00262-011-1185-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378844/
https://www.ncbi.nlm.nih.gov/pubmed/22198309
http://dx.doi.org/10.1007/s00262-011-1185-1

Ejemplares similares